Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Efficacy and Safety of the Irinotecan, Capecitabine, and Oxaliplatin (Iox) Regimen in Metastatic Gastric Cancer: A Single Arm Phase Ii Trial



Anvari S1 ; Alimoghaddam K1 ; Kasaeian A1 ; Vaezi M1 ; Rajaeinejad M2 ; Zokaasadi M1 ; Fumani HK1 ; Ghavamzadeh A1
Authors

Source: Middle East Journal of Cancer Published:2019

Abstract

Background: Gastric cancer is one of the most common malignancies worldwide with a high case mortality rate. In metastatic gastric cancer, a proper combination of chemotherapy could increase the survival rate. The goal of this study is to evaluate the efficacy and safety of the combination regimen of irinotecan, oxaliplatin, and Xeloda in metastatic gastric cancer. Methods: A total of 45 patients with metastatic gastric cancer and good performance status according to the Eastern Cooperative Oncology Group (score: 0-1) received the irinotecan, oxaliplatin, and Xeloda chemotherapy regimen. Demographic data, responses to treatment, and adverse effects were gathered for all cases. Overall survival and progression-free survival rates for patients were calculated using the Kaplan-Meier estimate. Results: Patients’ mean age was 58.3 ± 11.3 years (range: 24-81). There were 73.4% male patients and 26.6% female patients. Anorexia and weight loss were the most common symptoms. Overall response rate was 50%. The majority of toxicities were anemia, nausea and vomiting (grades 1 and 2), diarrhea (grades 1 and 2), neutropenia, alopecia, and hand and foot syndrome. The one-year progression-free survival rate was 31.5 ± 7.5%, whereas the two-year progression-free survival rate was zero. The one-year overall survival rate was 34.91 ± 8.5%. Patients had a two-year overall survival rate of 7.7 ± 6.6%. Diffuse type cancer was linked to an inferior outcome. Conclusion: Regardless of our limited number of patients, this combination could be a suitable regimen for metastatic gastric cancer in terms of low toxicity, acceptable response rate, and survival results. © 2019, Shiraz University of Medical Sciences. All rights reserved.
Related Docs
View other Related Docs
1. Postoperative Net Survival of Gastric Adenocarcinoma at Imam Khomeini Hospital in Tehran: Estimating in a Relative-Survival Framework, Koomesh (2018)
2. Estimating the Net Survival of Patients With Gastric Cancer in Iran in a Relative Survival Framework, Iranian Journal of Medical Sciences (2018)
3. Prevalence of Gastric Precancerous Lesions Among Chronic Dyspeptic Patients and Related Common Risk Factors, European Journal of Cancer Prevention (2015)
Experts (# of related papers)
View all Related Experts
Hojjat Zeraati (3)
Reza Malekzadeh (2)
Other Related Docs
4. Post-Marketing Surveillance of a Generic Oxaliplatin (Alvoxalⓡ) in Iranian Patients With Cancer, Current Therapeutic Research - Clinical and Experimental (2022)
5. Relationship Between Demographic and Pathological Characteristics on the 5-Year Survival Rate of Gastric Cancer Patients in Tehran Province, Tehran University Medical Journal (2022)
6. Prediction of Response to Irinotecan and Drug Toxicity Based on Pharmacogenomics Test: A Prospective Case Study in Advanced Colorectal Cancer, Asian Pacific Journal of Cancer Prevention (2017)
7. Flot (A Chemotherapy Regimen for Gastric/Esophagogastric Junction Cancer): To Be Treated As a Highly Emetogenic Regimen or a Moderately Emetogenic One? Comparison of the Emetogenic Potential of Flot Versus Folfox and Tac Regimens, Supportive Care in Cancer (2022)
8. Estimating the Treatment Effect in Patients With Gastric Cancer in the Presence of Noncompliance, Gastroenterology and Hepatology from Bed to Bench (2021)
9. Estimating Postoperative Survival of Gastric Cancer Patients and Factors Affecting It in Iran: Based on a Tnm-7 Staging System, Acta Medica Iranica (2016)
10. Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Cancer: Phase Ii Clinical Trial, International Journal of Radiation Research (2015)
11. Is There Any Difference Between Eastern and Western Clinical Practice Guidelines in Management of Gastric Cancer?, Cancer Reports (2024)
12. Annual Trends of Gastrointestinal Cancers Mortality in Iran During 1990-2015; Nasbod Study, Archives of Iranian Medicine (2018)
13. Survival Benefit of Induction Chemotherapy With Paclitaxel and Carboplatin Followed by Chemoradiation Versus Postoperative Treatment in Locally Advanced Gastric Cancer: A Retrospective Cohort Study, Journal of Gastrointestinal Cancer (2024)
14. Influential Factors on Survival in Gastric Cancer: A Single-Center Study, Journal of Research in Medical Sciences (2022)
15. Evaluation of Response to Preoperative Chemotherapy Versus Surgery Alone in Gastroesophageal Cancer: Tumor Resectability, Pathologic Results and Post-Operative Complications, Asian Pacific Journal of Cancer Prevention (2016)
16. Estimates of One, Three, and Five Year Survival Rate of Patients With Gastric Cancer in Iran Using the Meta-Analysis Method, Iranian Journal of Epidemiology (2015)
17. Clinicopathological Factors and Gastric Cancer Prognosis in the Iranian Population: A Meta-Analysis, Asian Pacific Journal of Cancer Prevention (2015)
18. Immune Checkpoint Inhibitors Plus Chemotherapy Versus Chemotherapy Alone As First-Line Therapy for Advanced Gastric and Esophageal Cancers: A Systematic Review and Meta-Analysis, International Immunopharmacology (2022)
19. The Promising Role of Monoclonal Antibodies for Gastric Cancer Treatment, Immunotherapy (2019)
20. Clinicopathological Factors Predisposing to No. 12A Lymph Node Metastasis in Gastric Cancer: A Prospective Cohort Analysis, Cancer Reports (2025)